13 Facts About Docetaxel

Docetaxel, sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer.

Docetaxel induced pneumotoxicity is a well recognized adverse effect which has to be identified timely and treated after withholding the drug Side effects are more common in people with liver problems.

Docetaxel was patented in 1986 and approved for medical use in 1995.

Docetaxel is used in the treatment of various cancers, including breast, lung, prostate, gastric, head and neck, and ovarian cancer.

Docetaxel has been found to have greater cellular uptake and is retained longer intracellularly than paclitaxel allowing docetaxel treatment to be effective with a smaller dose, leading to fewer and less severe adverse effects.

Related searches

Docetaxel is administered via a one-hour infusion every three weeks over ten or more cycles.

Docetaxel is used in combination with capecitabine, a DNA synthesis inhibitor.

Docetaxel-induced DPLD is a fatal adverse effect, which can be managed by the cessation of the drug and starting on steroids in adequate doses.

Docetaxel is of the chemotherapy drug class; taxane, and is a semi-synthetic analogue of paclitaxel, an extract from the bark of the rare Pacific yew tree, Taxus brevifolia.

Docetaxel interacted little with erythrocytes and was unaffected by the polysorbate 80 in its storage medium.

Docetaxel is mainly metabolised in the liver by the cytochrome P450 CYP3A4 and CYP3A5 subfamilies of isoenzymes.

Docetaxel activity is significantly greater in ovarian and breast tumours than for lung tumours.

Docetaxel is marketed worldwide under the name Taxotere by Sanofi-Aventis as well as Docefrez by Sun Pharma Global and Zytax by Zydus.